State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech

He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing.